Home » Topics » Disease categories and therapies » Urology

Urology
RSS

U.K.'s MHRA reclassifies Viagra for sale as non-prescription, pharmacy medicine

Dec. 1, 2017

Enanta patents novel farnesoid X receptor agonists

Dec. 1, 2017

Nippon Chemiphar completes phase I trial of NC-2500 and preclinical studies with NC-2700

Nov. 30, 2017

Kyowa Hakko Kirin licenses tenapanor rights in Japan from Ardelyx

Nov. 28, 2017

MA-0217 as a promising new agent for ischemic acute kidney injury

Nov. 27, 2017

New vasopressin receptor antagonists presented by Bayer

Nov. 23, 2017

Ardelyx discontinues development of RDX-7675

Nov. 22, 2017

Calliditas Therapeutics gives update on phase III study plans for Nefecon

Nov. 21, 2017

FDA extends review period for Tlando NDA

Nov. 20, 2017

Bayer discovers new vasopressin receptor antagonists

Nov. 17, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.